JGJúnia Maria Geraldo Gomes

Júnia Maria Geraldo Gomes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Júnia Maria Geraldo Gomes has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effects of Pumpkin ( Cucurbita spp.) on Glycemic and Type 2 Diabetes–Related Metabolic Biomarkers: A Systematic Review of Controlled Clinical Trials

    by Ke Ye, Flávia Galvão Cândido, Juliana de Souza Ramos, Mariana Julião Guilarducci, Nathalia Sernizon Guimarães, Huaqing Liu, Júnia Maria Geraldo Gomes

    Context: Pumpkin (Cucurbita spp.) is a versatile, low-cost, widely used plant product with potential to promote glycemic control. However, clinical evidence regarding its antihyperglycemic efficacy remains inconsistent. Objective: The primary aim was to investigate the antihyperglycemic effects of pumpkin in human nutrition; the secondary aim was to assess pumpkin’s impact on type 2 diabetes mellitus (T2DM)-related metabolic biomarkers. Data Source: A systematic review was performed by searching databases (MEDLINE/PubMed, Embase, and Cochrane Library/Central) until March 2025 and included controlled clinical trials assessing the effects of pumpkin or its by-products on glucose outcomes and T2DM-related metabolic biomarkers in adults with or without T2DM. Data Extraction: All studies were independently screened and extracted by 2 researchers. In the case of disagreement, a third researcher was consulted. Data Analysis: From 198 records screened, 9 controlled clinical trials (n = 316 participants) were selected for qualitative analysis. Conclusions: Pumpkin and its by-products have potential to be used as adjuvants in the prevention and/or treatment of T2DM. More high-quality and long-term clinical trials are needed to confirm this evidence. Systematic Review Registration: PROSPERO registration No. CRD42022376276.


  • Open Access

    Propolis supplementation modulates gut microbiota in rodent models: a systematic review

    by Geovana Nazareth Moura, Maria Eduarda Silva Careli, Sônia Maria de Figueiredo, Anny Caroline Messias, Mariana Julião Guilarducci, Nathalia Sernizon Guimarães, Júnia Maria Geraldo Gomes

  • Effects of cinnamon supplementation on metabolic biomarkers in individuals with type 2 diabetes: a systematic review and meta-analysis

    by Suzana Laís de Moura, Bruna Gabrielle Rocha Gomes, Mariana Julião Guilarducci, Olívia Gonçalves Leão Coelho, Nathalia Sernizon Guimarães, Júnia Maria Geraldo Gomes

    The global prevalence of type 2 diabetes mellitus (DM2) has been rising significantly over the years. Recent studies have shown beneficial effects of cinnamon on metabolic biomarkers. The objective of this review was to assess the effect of cinnamon supplementation on metabolic biomarkers in patients with DM2. The Pubmed/MEDLINE, Cochrane CENTRAL, and Embase databases were searched up to November 10, 2022. A systematic search was performed for randomized controlled trials (RCTs) evaluating the effect of cinnamon supplementation on metabolic biomarkers, in adults and the elderly with DM2, and comparing the data for a cinnamon intervention group with that for a placebo group or a control group. The main exclusion criteria were studies (1) with other types of diabetes (ie, gestational diabetes or type 1 diabetes), (2) without cinnamon consumption, (3) that did not evaluate metabolic biomarkers, or (4) in vitro and animal studies. Two researchers independently screened 924 records, evaluated full-text studies, extracted data, and appraised their quality. A third researcher was consulted to resolve any discrepancies. The data were pooled using random-effects models and expressed as the weighted mean difference (WMD) with 95% CI. Heterogeneity was assessed using Cochran’s Q test and quantified using I2 statistics. Risk of bias was assessed using the Joanna Briggs Institute (JBI) instrument. Sensitivity analysis and the GRADE system were used to assess the robustness and certainty of the findings. In total, 28 RCTs with a duration ranging from 30 to 120 days and a total enrollment of 3054 patients with DM2 were included. Participants consuming cinnamon showed a significant reduction in fasting blood glucose (FBG) (WMD: −15.26 mg/dL; 95% CI: −22.23 to −8.30; I2 = 88%), postprandial glucose (WMD: −39.22 mg/dL; 95% CI: −63.90 to −14.55; I2 = 100%), HbA1c (WMD: −0.56 mg/dL; 95% CI: −0.99 to −0.13; I2 = 94%), and HOMA-IR (WMD = −0.76, 95% CI: −1.13 to −0.39; I2 = 22%) compared with the control group. An intervention of cinnamon in capsule form reduced FBG (WMD:−18.43 mg/dL, 95% CI: −26.32 to −10.53; I2 = 89%), postprandial glucose (WMD: −44.83 mg/dL, 95% CI: −70.67 to −18.99; I2 = 100%), HbA1c (WMD: −0.56 mg/dL, 95% CI: −1.02 to −0.09; I2 = 94%), total cholesterol (WMD: −13.39 mg/dL; 95% CI: −24.71 to −2.07; I2 = 96%), LDL-C (WMD: −6.49 mg/dL, 95% CI: −12.69 to −0.29; I2 = 92%), and triglycerides (WND: −19.75 mg/dL; 95% CI, −33.71 to −5.80; I2 = 88%). Both doses (≤2 g/day and >2 g/day) reduced FBG and postprandial glucose. Only cinnamon doses of ≤2 g/day reduced HbA1c (WMD: −0.68 mg/dL, 95% CI: −1.16 to −0.1; I2 = 92%), HOMA-IR (WMD: −0.94 mg/dL; 95% CI: −1.21 to −0.67; I2 = 0%), and BMI (WMD: −1.18 kg/m2; 95% CI: −1.97 to −0.39; I2 = 0%). The data suggest that cinnamon improves the glycemic and lipid profile and reduces the BMI, particularly in DM2 patients who receive cinnamon supplementation in capsule form and at a dose of ≤2 g/day. PROSPERO registration no. CRD42022370332.


  • Open Access

    Effect of fructose on the intestinal microbiota: a systematic review of randomized clinical trials

    by Letícia Lourenço da Silva, Rayane Rodrigues Lopes, Mariana Julião Guilarducci, Olívia Gonçalves Leão Coelho, Flávia Galvão Cândido, Nathalia Sernizon Guimarães, Júnia Maria Geraldo Gomes

    Background: Preclinical data suggest that at least part of the harmful effects of excessive fructose consumption are due to alterations in the intestinal microbiota, which may be associated with a number of metabolic diseases, such as diabetes mellitus, obesity, inflammatory bowel disease, metabolic syndrome, and non-alcoholic fatty liver disease. Objective: The aim of this systematic review is to evaluate the effects of fructose consumption on the human intestinal microbiota. Methods: A systematic search was carried out in electronic databases: MEDLINE, Embase, and Cochrane Library without restriction to a year of publication and language. Inclusion criteria were primary articles that evaluated the effect of fructose consumption on the human intestinal microbiota. Results: Five randomized clinical trials were include. It was observed that the composition of the human intestinal microbiota seems to be altered differently in response to fructose consumption at distinct sources and concentrations. Overall, fructose administration increased bacterial profile associated with inflammation, hepatic steatosis, butyrate production, and inhibition of microbial aerobic respiration in the ileum (Proteobacteria, Actinobacteria, Anaerostipes, and Faecalibacterium). The administration of fructose showed a negative correlation for Firmicutes and a positive correlation for Parabacteroides in relation to total cholesterol and LDL-c. However, studies had great methodological heterogeneity and presented high risk of bias. Conclusion: Fructose administration affects the composition of human intestinal microbiota. More studies are needed to reach definitive conclusions.

  • Open Access

    Prevalence and factors associated with dietary adherence in individuals with type 2 diabetes mellitus in Brazil: a systematic review with meta-analysis

    by Ellen Jaqueline Ramos, Larissa Thais Braz Pereira, Mariana Julião Guilarducci, Arlindo Leandro Gomes, Nathalia Sernizon Guimarães, Flávia Galvão Cândido, Olívia Gonçalves Leão Coelho, Júnia Maria Geraldo Gomes

    Objetivo: A baixa adesão ao tratamento é um grande desafio enfrentado pelos profissionais de saúde durante o manejo do diabetes tipo 2 (DM2). Objetivo: Este estudo teve como objetivo avaliar a prevalência e os fatores de risco relacionados à adesão alimentar em indivíduos com DM2 no Brasil. Métodos: PubMed, Embase, CoChrane Library e SciELO/LILACS foram pesquisados ​​sem restrição de ano de publicação e idioma. Resultados: De 3.713 estudos, 14 artigos envolvendo 2.962 indivíduos com DM2 foram elegíveis. A proporção combinada de adesão à dieta foi de 41% (IC 95%: 0,267-0,562, p< 0,001; I 2 = 98,81%, p< 0,001), com os mais altos 78% e os mais baixos 3%. A proporção combinada de não adesão à dieta foi de 51% (IC 95%: 0,268-0,754, p<0,001; I²= 99,25%, p<0,001), sendo a maior de 98% e a menor de 9%. Os principais fatores de risco para a não adesão ao tratamento nutricional foram baixa escolaridade, baixa renda e multimorbidade. Conclusão: A baixa adesão à dieta alimentar é uma preocupação durante o aconselhamento nutricional de indivíduos com DM2 no Brasil. Introduction: Low adherence to the treatment is a major challenge faced by health professionals during the management of type 2 diabetes. Objective: To assess the prevalence and risk factors related to dietary adherence in individuals living with type 2 diabetes in Brazil. Material and Methods: PubMed, Embase, Cochrane Library and SciELO/Lilacs were searched without restriction to a year of publication and language. Results: From 3713 studies, 14 articles involving 2962 individuals living with type 2 diabetes were eligible. The combined proportion of adherence to the diet was 41% (95% CI: 0.267-0.562, p< 0.001; I2= 98.81%, p<0.001), with the highest 78% and lowest 3%. The combined proportion of nonadherence to the diet was 51% (95% CI: 0.268-0.754, p<0.001; I²= 99.25%, p<0.001), with the highest being 98% and the lowest being 9%. The main risk factors for nonadherence to nutritional treatment were low education, low income, and multimorbidity. Conclusion: Low adherence to the diet is a concern during nutritional counseling of individuals living with type 2 diabetes in Brazil.

  • Effect of fish-oil supplementation on the glycemic and lipidemic profiles of pregnant women: a systematic review and meta-analysis

    by Julie M Silveira, Thassia S Ribeiro, Mariana J Guilarducci, Marcela Gomes Reis, Renata A L Vieira, Nathalia S Guimarães, Júnia M G Gomes

    Pregnant women have physiological metabolic changes in glycemic and lipid profiles that are essential for fetal development. The aim of this systematic review was to analyze the effects of fish-oil-capsule supplementation on the glycemic and lipid profiles of pregnant women. A systematic search was conducted of the MEDLINE (by PubMed), Embase, Cochrane Library (CENTRAL) databases and gray literature, including preprints for all relevant studies published in English, with no date restrictions. The estimated pooled results were analyzed using a random-effects model and represented by mean differences (MDs) and corresponding 95% confidence intervals (CIs). The analyses were performed with R software, version 4.2.1, using the “Meta” packages, versions 6.0-0. Fifteen eligible studies were included after screening. In a pooled analysis, overall fish-oil supplementation had no effect on parameters compared with placebo. In the subgroup analysis, fish-oil supplementation may be beneficial in insulin (MD: –2.11 IU/mL; 95% CI: –3.86, –0.36) and homeostasis model assessment of insulin resistance (HOMA-IR) (MD: –0.71; 95% CI: –1.14, –0.29) indices, with heterogeneity (I2 =0%) among pregnant women with diabetes mellitus. In the subgroup with doses of eicosapentaenoic acid (EPA) below 200 mg, there was a reduction in HOMA-IR in the intervention group (MD: –0.60; 95% CI: –1.14, –0.06). Pregnant women taking fish-oil capsules showed significant beneficial changes in the subgroups of type 2 diabetes and EPA dosages below 200 mg for insulin and HOMA-IR.


  • Association of vitamin D and cognition in people with type 2 diabetes: a systematic review

    by Alice D da Silva, Julia S Oliveira, Isabela C de Castro, Wanderléia C Paiva, Júnia M G Gomes, Laura C J P Pimenta

    There is a high prevalence of vitamin D deficiency and impaired cognitive function in people with type 2 diabetes mellitus (T2DM). To critically and systematically review the literature on the association between vitamin D status and cognitive performance in people with type 2 diabetes. This review was conducted according to PRISMA recommendations. MEDLINE, SCOPUS, the Cochrane Library, and Web of Science databases were searched using the terms “Diabetes Mellitus, Type 2”, “Cognitive Function”, and “Vitamin D”. Eight observational and 1 randomized study were included, containing data of 14 648 adult and elderly individuals (19–74 y). All extracted data were compiled, compared, and critically analyzed. There is no strong evidence that lower serum concentrations of vitamin D and vitamin D–binding protein are associated with worsening cognitive function in individuals with T2DM. Vitamin D supplementation (12 wk) improved the scores of some executive functioning tests, although there was no difference between low doses (5000 IU/wk) and high doses (50 000 IU/wk). There is no high-quality evidence demonstrating an association between vitamin D status and cognitive function, or clinical benefits on cognition from vitamin D supplementation in individuals with T2DM. Future studies are needed. Systematic Review Registration:PROSPERO registration no. CRD42021261520.


  • Open Access

    Consumption of ultra-processed foods and associated factors in children from Barbacena (MG), Brazil

    by Marlene de Melo Fonseca, Rafaela Vitoria Guilherme Coimbra, Julia Silva e Oliveira, Anne Danieli Nascimento Soares, Júnia Maria Geraldo Gomes

    Objective: To evaluate the prevalence of ultra-processed food consumption and associated factors among children enrolled in the public school system of the city of Barbacena, Minas Gerais, Brazil. Methods: This is a cross-sectional study conducted with schoolchildren aged 7–9 years, of both sexes, enrolled in state public schools. Food intake was assessed using the Previous Day Food Questionnaire and the level of physical activity by the Previous Day Physical Activity Questionnaire. The listed foods were classified according to the extent and purpose of industrial processing, using the NOVA classification. Pearson’s χ2 test, Fisher’s exact test, χ2 with Yates correction, and Poisson regression were used in the statistical analysis, estimating the crude and adjusted prevalence ratio, with 95% confidence intervals. Results: The prevalence of daily ultra-processed food consumption was 69.6%. After adjusted analyses, the consumption of ultra-processed food was associated with the omission of breakfast, mid-afternoon snack, supper, low physical activity, and consumption of risk foods. On the other hand, consumption of in natura or minimally processed foods was associated with older age, the consumption of lunch, mid-afternoon snack, dinner, and protective foods. Conclusions: There is a high prevalence of ultra-processed foods consumption, associated with unhealthy dietary habits among schoolchildren. This highlights the need for nutritional counseling and educational actions, favoring healthy eating in childhood.


  • Food Aversion during Cancer Treatment: A Systematic Review

    by Aline de Araújo Pereira, Emylliane Santana dos Reis, Mariana Julião Guilarducci, Julia Silva e Oliveira, Júnia Maria Geraldo Gomes

    Individuals with cancer often present food aversion after initiation of anti-tumor treatment, which may impair nutritional status. We aim to assess the prevalence and factors associated with food aversion during cancer treatment. Articles from three databases were searched: MEDLINE, EMBASE and Cochrane Library. English was used, with no restriction on the year of publication. Inclusion criteria were original articles that evaluated food aversion in adults and the elderly undergoing chemotherapy and/or radiotherapy treatment. Fifteen articles were included. A high prevalence of food aversion (21–62%) was observed, with meat considered the most aversive food. The aversion is usually transient and may be due to gastrointestinal problems, such as nausea and vomiting, caused by chemotherapy or radiotherapy treatment, and even psychological and emotional issues. Offering a new food before the beginning of treatment seems to be an effective strategy to reduce aversion, combined with nutritional and psychological monitoring. Cancer patients have a high prevalence of food aversion. Multidisciplinary care can minimize the consequences of cancer treatment.


  • Open Access

    Association between abdominal obesity, screen time and sleep in adolescents

    by Isabela dos Reis de Oliveira, Nathália Maximiano Soares Maciel, Bianca Tomaz da Costa, Anne Danieli Nascimento Soares, Júnia Maria Geraldo Gomes